Is It Time To Revisit Inspire Medical Systems (INSP) After A Sharp Share Price Pullback?

Simply Wall St.04-19

If you are wondering whether Inspire Medical Systems at around US$57.59 is priced attractively or not, it helps to start by separating story from numbers. The share price has moved 6.6% over the last ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628754196?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-04-19 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628754196","market":"nz","top_or_hot":-1,"title":"Is It Time To Revisit Inspire Medical Systems (INSP) After A Sharp Share Price Pullback?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Inspire Medical Systems at around US$57.59 is priced attractively or not, it helps to start by separating story from numbers. The share price has moved 6.6% over the last ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-it-time-to-revisit-inspire-medical-systems-insp-after-a-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Revisit Inspire Medical Systems (INSP) After A Sharp Share Price Pullback?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Revisit Inspire Medical Systems (INSP) After A Sharp Share Price Pullback?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-19 05:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-it-time-to-revisit-inspire-medical-systems-insp-after-a-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Inspire Medical Systems at around US$57.59 is priced attractively or not, it helps to start by separating story from numbers. The share price has moved 6.6% over the last ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-it-time-to-revisit-inspire-medical-systems-insp-after-a-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-it-time-to-revisit-inspire-medical-systems-insp-after-a-s","article_id":"2628754196","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-it-time-to-revisit-inspire-medical-systems-insp-after-a-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628754196","pubTimestamp":1776546373,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Inspire Medical Systems at around US$57.59 is priced attractively or not, it helps to start by separating story from numbers.\nThe share price has moved 6.6% over the last 7 days and 2.1% over the past month, set against a much weaker year to date return of 37.6% and a 1 year return of 61.7%.\nRecent coverage has focused on the company as a medical device player in sleep apnea treatment, with attention on how its growth profile and competitive position compare with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4167":"医疗保健技术","BK4082":"医疗保健设备","INSP":"Inspire Medical Systems","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"股价大幅回调后，是时候重新审视Inspire Medical Systems(INSP)了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"INSP":1.5},"content_text":"If you are wondering whether Inspire Medical Systems at around US$57.59 is priced attractively or not, it helps to start by separating story from numbers. The share price has moved 6.6% over the last 7 days and 2.1% over the past month, set against a much weaker year to date return of 37.6% and a 1 year return of 61.7%. Recent coverage has focused on the company as a medical device player in sleep apnea treatment, with attention on how its growth profile and competitive position compare with other specialized healthcare names. That context matters when you weigh up a share price that has pulled back over 3 and 5 years, with returns of 79.1% and 74.7% respectively. Simply Wall St currently gives Inspire Medical Systems a valuation score of 5 out of 6 based on six separate checks for potential undervaluation. The next sections will compare what different valuation methods say about the stock, while keeping an even more helpful way to think about value for the end of the article.  Find out why Inspire Medical Systems's -61.7% return over the last year is lagging behind its peers. AdvertisementApproach 1: Inspire Medical Systems Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes projected future cash flows and then discounts them back to today using a required rate of return to estimate what the business might be worth right now. For Inspire Medical Systems, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow sits at about $77.5 million. Analyst estimates and extrapolations together produce ten year free cash flow projections, with discounted values such as $147.5 million in 2026, $162.2 million in 2027 and $157.7 million in 2028, extending through to 2035 using Simply Wall St extrapolations. When all of those discounted cash flows are added up, the model arrives at an estimated intrinsic value of about $146.92 per share. Compared with the recent share price of around $57.59, this implies an intrinsic discount of 60.8%. On this DCF view, the shares screen as undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Inspire Medical Systems is undervalued by 60.8%. Track this in your watchlist or portfolio, or discover 59 more high quality undervalued stocks. INSP Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Inspire Medical Systems. Approach 2: Inspire Medical Systems Price vs Earnings For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for a share directly to the earnings that support it. In general, higher growth expectations and lower perceived risk can justify a higher P/E, while slower growth or higher risk tend to align with a lower, more conservative multiple. Inspire Medical Systems currently trades on a P/E of about 11.4x. That sits well below the Medical Equipment industry average of roughly 26.0x and the peer group average of about 77.7x. Simply Wall St also calculates a “Fair Ratio” for the stock of around 15.7x, which is the P/E level suggested by its earnings growth profile, industry, profit margins, market cap and identified risks. This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts for the company’s own characteristics rather than assuming that all medical equipment names should trade on the same multiple. Setting the current P/E of 11.4x against the Fair Ratio of 15.7x indicates that the shares are trading below the level implied by those fundamentals. Result: UNDERVALUED NYSE:INSP P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Inspire Medical Systems Narrative Earlier sections compared Inspire Medical Systems using DCF and P/E, but a more useful way to think about value is through Narratives, where you set a clear story for the company and tie that story to explicit assumptions for future revenue, earnings, margins and a fair value estimate, then compare that to the current price. On Simply Wall St's Community page, Narratives let you do this in a structured and accessible way, connecting your view of Inspire Medical Systems, such as cautious expectations around reimbursement and slower growth or a more optimistic view linked to faster Inspire V adoption and stronger margins, directly to a forecast and resulting fair value. For Inspire Medical Systems today, one investor might lean toward a cautious Narrative with a fair value around US$56 based on slower revenue growth, lower margins and a P/E near 30x in 2029. Another might back a more optimistic Narrative with a fair value near US$212 that assumes higher revenue growth, improving margins and a P/E near 47x in 2028. As new information like earnings, CMS updates or guidance changes arrives, these Narratives can be updated so you can keep checking how each fair value compares with the live share price. For Inspire Medical Systems, we will make it really easy for you with previews of two leading Inspire Medical Systems Narratives: Start with this bullish take if you think the current pricing is too cautious. 🐂 Inspire Medical Systems Bull Case Fair value: US$79.42 Implied discount to this fair value versus the last close of US$57.59: about 27.5%. Revenue growth assumption: 8.01% a year.  Analysts in this camp see recent operational and coding issues as temporary, with CMS clarity and Inspire V adoption helping support future procedure volumes and earnings power. The narrative builds in mid single digit to high single digit annual revenue growth, a step down in profit margins from current levels, and a future P/E of about 26.5x on 2029 earnings. It leans on broad sleep apnea demand, reimbursement support and improved center productivity, while flagging risks around rollout execution, reimbursement policy shifts and possible changes in treatment preferences.  Or start here if you think the market is already giving Inspire Medical Systems the benefit of the doubt. 🐻 Inspire Medical Systems Bear Case Fair value: US$56.00 Implied premium to this fair value versus the last close of US$57.59: about 2.8%. Revenue growth assumption: 5.64% a year.  This view leans on reimbursement pressure, slower center expansion and higher operating costs as constraints on revenue growth and margins despite ongoing demand for sleep apnea treatment. The bearish cohort assumes mid single digit annual revenue growth, margin compression toward the mid single digits and a future P/E of about 30.6x on 2029 earnings, which is higher than the current industry P/E used in the narrative. Key watchpoints include the Inspire V rollout, competition from at home or non implant options, legal and compliance costs and the risk that value based care models weigh on pricing and long term earnings potential.  Use these two Narratives as reference points, then adjust the growth, margins, P/E and risk assumptions until the story lines up with how you see Inspire Medical Systems and what you think the shares are worth at today’s price. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Inspire Medical Systems on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. Do you think there's more to the story for Inspire Medical Systems? Head over to our Community to see what others are saying! NYSE:INSP 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628754196","isCrawlerRequest":true}